LivaNova plc Secures Regulatory Approval for Essenz Perfusion System in China, Expanding Market Reach for Heart-Lung Machines
LivaNova PLC, a leader in medical technology, has announced the commercial launch of its Essenz™ Perfusion System in China, following regulatory approval from China's National Medical Products Administration (NMPA). This launch marks a significant step for LivaNova as China represents the second-largest market for the company's heart-lung machines, following the United States. The Essenz Perfusion System, designed with input from over 300 perfusionists worldwide, offers a patient-tailored perfusion approach that enhances clinical workflows and patient care during cardiopulmonary bypass procedures. With this approval, the system is now available in several major markets, including Europe, Canada, Australia, Japan, and the United Arab Emirates, supporting over 100,000 patients globally since its launch in February 2023.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livanova plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20250818865276) on August 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.